An editor and writer specialising in pharma, biotech and healthcare, Dominic Tyer is pharmaphorum's creative and editorial director and interim managing editor.
The industry has experienced a sustained period of change since its blockbuster heyday in the 1990s and continues to evolve, with significant ramifications for new pharmaceutical launches.<
Janssen has won US approval for its once-daily HIV pill Symtuza (D/C/F/TAF), which it hopes will improve patient adherence and resistance to treatment.
Otsuka is paying $430 million for a US clinical-stage biotech company it hopes will act as a ‘drug creation engine’ to accelerate its research into kidney diseases.
